Pharmacist-led program to improve venous thromboembolism prophylaxis in a community hospital

American Journal of Health-System Pharmacy

Volumn 65, Issue 17, 2008, Pages 1643-1647

  Bauer, Jered B ^a,d   Chun, David S ^b   Karpinski, Todd A ^c  

^a Broadlane   (United States)

^b St Elizabeth's Hospital   (United States)

^c Broadlane

^d Operations Department   (United States)

Author keywords

Anticoagulants; Clinical pharmacists; Clinical pharmacy; Heparin; Pharmaceutical services; Thromboembolism

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

COMMUNITY HOSPITAL; DOPPLER ECHOGRAPHY; HOSPITAL ADMISSION; HUMAN; PHARMACIST; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; VENOUS THROMBOEMBOLISM;

EID: 51649095868     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070595     Document Type: Review

References (8)

1. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation. 1996; 93:2212-45.
2. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med. 1989; 82:203-5.
3. Goldhaber SZ, Tapson VF. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004; 93:259-62.
4. National Quality Forum. National consensus standards for the prevention and care of venous thromboembolism (including deep vein thrombosis and pulmonary embolism). www.qualityforum.org/projects/ongoing/vte/index.asp (accessed 2007 Aug 8).
5. Geerts WH, Pineo FP, Heit JA et al. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004; 126:S338-400.
6. Gärdlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet. 1996; 347:1357-61.
7. MacDougall DA, Feliu AL, Boccuzzi SJ et al. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health-Syst Pharm. 2006; 63(suppl 6):S5-15.
8. Samama MM, Cohen AT, Darmon JY et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999; 341:793-800.